Alzheimer disease (AD) is characterized by progressive cognitive decline in older
individuals accompanied by the presence of two pathological protein aggregates—amyloid …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Alzheimer's disease (AD) is a neurodegenerative disease associated with human aging.
Ten percent of individuals over 65 years have AD and its prevalence continues to rise with …

Scientific advances over the last four decades have steadily infused the Alzheimer's disease
(AD) field with great optimism that therapies targeting Aβ, amyloid, tau, and innate immune …

Peripheral inflammation, defined as inflammation that occurs outside the central nervous
system, is an age-related phenomenon that has been identified as a risk factor for …

The current clinical trial landscape targeting Alzheimer's disease (AD) is reviewed in the
context of studies completed from 2019 to 2021. This review focuses on available data for …

Chemotherapeutic agents may adversely affect the nervous system, including the neural
precursor cells as well as the white matter. Although the mechanisms are not completely …

Alzheimer's Disease (AD) is one of the most devastating age-related disorder causing
significant social and economic burden worldwide. It affects the cognitive and social …

The field of Alzheimer's disease (AD) research critically lacks an all-inclusive etiology theory
that would integrate existing hypotheses and explain the heterogeneity of disease trajectory …

The innate immune system plays key roles in controlling Alzheimer's disease (AD), while
secreting cytokines to eliminate pathogens and regulating brain homeostasis. Recent …